Antibiotics in the prevention and treatment of coronary heart disease

Journal of Infectious Diseases

Volumn 181, Issue 6 SUPPL. 3, 2000, Pages

  Meier, Christoph R ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 0034088318     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315632     Document Type: Conference Paper

References (61)

1. 1. American Heart Association. 2000 heart and stroke statistical update. Dallas: AHA, 1999.
2. 2. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular disease mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-48.
3. 3. Grayston JT, Kuo C, Wang S, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986;315:161-8.
4. 4. Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis 1985;151:832-9.
5. 5. Saikku P, Leinonen M, Mattila K, et al. Serologic evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
6. 6. Davidson M, Kuo C, Middaugh JP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998;98:628-33.
7. 7. Fagerberg B, Gnarpe J. Gnarpe H. Agewall S, Wikstrand J, Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease. Stroke 1999;30:299-305.
8. 8. Linnanmäki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993;87:1130-4.
9. 9. Mazzoli S, Tofani N, Fantini A, et al. Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 1998;135:15-20.
10. 10. Ossewaarde JM, Feskens EJM, De Vries A, Vallinga CE, Kromhout D. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998;120:93-9.
11. 11. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992;116:273-8.
12. 12. Strachan DP, Carrington D, Mendall MA. et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 1999;318:1035-40.
13. 13. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary heart disease. JAMA 1992;268:68-72.
14. 14. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999;99:1161-4.
15. 15. Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999;131:573-7.
16. 16. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999;150: 149-56.
17. 17. Bartels C, Maass M, Bein G, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999;99:879-82.
18. 18. Blasi F, Denti F, Erba M, et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996;34:2766-9.
19. 19. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma. Am J Pathol 1997; 150:1785-90.
20. 20. Kuo C, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-9.
21. 21. Kuo C, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 1995;92:6911-4.
22. 22. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555-61.
23. 23. Nystrom-Rosander C, Thelin S, Hjelm E, Lindquist O, Pahlson C, Friman G. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement. Stand J Infect Dis 1997; 29:361-5.
24. 24. Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor-Robinson D. Detection of widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 1996;49:102-6.
25. 25. Ramirez JA, Chlamydia pneumoniael Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996;125:979-82.
26. 26. Shor A, Kuo C, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992;82: 158-61.
27. 27. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997;65:4832-5.
28. 28. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97: 633-6.
29. 29. Bachmaier K, Neu N, de la Maza L, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999;283:1335-9.
30. 30. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-53.
31. 31. Falck G, Heyman L, Gnarpe J, Gnarpe H. Chlamydia pneumoniae (TWAR): a common agent in acute bronchitis. Scand J Infect Dis 1994;26:179-87.
32. 32. Grayston JT, Aldous MB, Easton A, et al. Evidence that Chlamydia pneumoniae causes pneumoniae and bronchitis. J Infect Dis 1993;168:1231-5.
33. 33. Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin Infect Dis 1995; 21(suppl 3):S244-52.
34. 34. Karvonen M, Tuomilehto J, Pitkäniemi J, Saikku P. The epidemic cycle of Chlamydia pneumoniae infection in eastern Finland, 1972-1987. Epidemiol Infect 1993;110:349-60.
35. 35. Kauppinnen MT, Herva E, Kujala P, Leinonen M, Saikku P, Syrjälä H. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172:1330-5.
36. 36. Cook PJ, Honeybourne D. Clinical aspects of Chlamydia pneumoniae infection. Presse Med 1995;24:278-82.
37. 37. Gnarpe J, Gnarpe H, Sundelöf B. Endemic prevalence of Chlamydia pneumoniae in subjectively healthy persons. Scand J Infect Dis 1991;23:387-8.
38. 38. Hyman CL, Roblin PM, Gaydos CA, Quinn TC, Schachter J, Hammerschlag MR. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment of polymerase chain reaction enzyme immunoassay and culture. Clin Infect Dis 1995;20: 1174-8.
39. 39. Hyman CL, Augenbraun MH, Roblin PM, Schachter J, Hammerschlag MR. Asymptomatic respiratory tract infections with Chlamydia pneumoniae TWAR. J Clin Microbiol 1991;29:2082-3.
40. 40. Beale AS, Masson ND. Susceptibility of Chlamydia pneumoniae to oral agents commonly used in the treatment of respiratory infection. J Antimicrob Chemother 1994;34:1072-5.
41. 41. Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. Antimicrob Agents Chemother 1998;42:2762-4.
42. 42. Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992;14:178-82.
43. 43. Hammerschlag MR. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother 1994; 38:1873-8.
44. 44. Kuo C, Jackson LA, Lee A, Grayston JT. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1996;40:2669-70.
45. 45. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-4.
46. 46. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
47. 47. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
48. 48. Gurfinkel E., Bozovich G, Beck E, Testa E, Livellara B, Mautner B for the ROXIS Study Group. Treatment with the antibiotic roxithromycin in patients with acute non Q-wave coronary syndromes. Eur Heart J 1999;20:121-7.
49. 49. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 1999;99:1540-7.
50. 50. Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 1996;20:693-705.
51. 51. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone 1998;22:33-8.
52. 52. Smith GN, Yu LP, Brandt KD, Capello WN. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol 1998;25:532-5.
53. 53. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
54. 54. Martin D, Bursill J. Qui MR, Breit SN, Campbell T. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet 1998;351: 1858-9.
55. 55. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-9.
56. 56. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time myocardial infarction. JAMA 1999;281:427-31.
57. 57. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 1999;5: 281-4.
58. 58. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-8.
59. 59. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiology Drug Safety 1992;1:347-9.
60. 60. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-99.
61. 61. Jick H, Garcia Rodriguez LA, Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998;352: 1767-70.